Amryt

Amryt is a global commercial-stage biopharmaceutical company developing treatments for rare and orphan diseases.

Resarch Center Chiesi Farmaceutici SpA Parma
Pharma

5 years after European nod, Chiesi wins FDA approval for Lamzede

Five years after gaining approval in Europe for Lamzede, Chiesi Farmaceutici has pushed it over the finish line in the United States.
Kevin Dunleavy Feb 17, 2023 10:09am
Accogli

After Amryt buy, Chiesi names Baxter vet Accogli its new CEO

Jan 30, 2023 2:00am
handshake

Chiesi gets jump-start on JPM buzz with $1.48B Amryt buyout

Jan 9, 2023 9:35am